“A tiny biotech controls agricultural technology that could end food shortages forever… And, in the process, render Monsanto GMOs obsolete.
“This development stands to make early investors 181 times their money in just a few years.
“It’s why Citigroup, Wells Fargo, and other financial powerhouses have teamed up to launch the little company that’s responsible for all of it.
“And you can get in on the action, too. But time’s running out…
“Picture editing a document on your computer… You see a phrase that you don’t like, so you highlight and delete it.
“Well, this analogy is the easiest way to explain how the technology of the little biotech I’ve been telling you about works.
“It’s called gene editing.
“You simply ‘snip’ parts of a plant’s DNA that are responsible for an unwanted trait and presto — the trait no longer exists.
“Want drought-resistant corn?
“Snip!”
So far, the little $10 company has used this gene-editing technology to develop food products that are near commercialization, including…
“Potatoes that you can store in the refrigerator, making them last far longer after you buy them.
“Wheat that could produce flour with up to three times more dietary fiber than the standard, thereby improving digestion, lowering cholesterol, stabilizing glucose levels, and helping to keep weight down.
“Reduced trans fat in soybean oil and lower saturated fat in canola oil, which studies show can lower the risk of heart disease.
“Wheat, corn, and rice that are immune to the devastating powdery mildew disease, resulting in farmers being able to forgo poisonous herbicides.”
And Stutman notes that “plants treated with this technology are not considered GMOs by the FDA,” which might help with public acceptance, and he says that means the approval process is much faster than it is with stuff like Monsanto’s GMO seeds.
Thinkolator says this ad is using some old data, which probably means that Stutman made the recommendation to his subscribers back in July or August and they’ve repackaged it into an ad, but that the stock being hinted at is Calyxt (CLXT).
And yes, Calyxt is a gene editing firm that’s focused on agriculture — the technology they’re building the company on is a proprietary editing technology called TALEN, which sounds similar to CRISPR/Cas9 but is not exactly the same.
Beyond the regulatory risk, of which I know nothing specific, there’s also the plain old “investor” risk — the lockup on that IPO expires on January 16, so that’s the date on which insiders could start selling if they want to. That often depresses the share price of IPOs roughly six months after they go public, so it’s possible that if you’re excited about this stock, there could be an opportunity buy when the insiders are selling in a month or so… though that, of course, is no guarantee, and that assumes they don’t release any exciting news that causes the stock to soar before that date.
Click for Full Text!
Poster Comment:
So many proposals from investor fantasy land show great promise until some glitch is encountered.